Sunday, September 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 24, 2025

The Zacks Analyst Blog Highlights Invesco, Johnson & Johnson, NiSource, Bunge Global and Morgan Stanley

View original at finance.yahoo.com
The Zacks Analyst Blog Highlights Invesco, Johnson & Johnson, NiSource, Bunge Global and Morgan Stanley For Immediate Release Chicago, IL – December 24, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Johnson & Johnson currently has a Zacks Rank #2 (Buy)

    80% confidence
  • Bunge pays out a quarterly dividend of 70 cents ($2.80 annualized) per share, yielding 3.06% at the current stock price; BG's payout ratio is 37%, with a five-year dividend growth rate of 8.58%

    80% confidence
  • Johnson & Johnson currently has a Zacks Rank #2 (Buy)

    80% confidence
  • Morgan Stanley currently has a Zacks Rank #2 (Buy)

    80% confidence
  • Zacks top stock-picking strategies have returned average gains of +48.4%, +50.2% and +56.7% per year since 2000, compared to the S&P's +7.7% average gain per year

    80% confidence
  • Invesco's robust AUM balance, diverse product offerings, strong balance sheet and global presence will keep supporting financials, and synergies from acquisitions will keep aiding profitability

    80% confidence
  • Invesco currently sports a Zacks Rank #1 (Strong Buy)

    80% confidence
  • Invesco currently sports a Zacks Rank #1 (Strong Buy)

    80% confidence
  • Real GDP growth for 2025 is projected at about 2%, reflecting steady but below-trend expansion compared with historical averages

    80% confidence
  • Real GDP growth for 2025 is projected at about 2%, reflecting steady but below-trend expansion compared with historical averages

    80% confidence
  • Bunge is executing a fundamental transformation anchored by the Viterra merger, expanding global origination, processing scale and logistics efficiency

    80% confidence
  • Morgan Stanley currently has a Zacks Rank #2 (Buy)

    80% confidence
  • NiSource pays out a quarterly dividend of 28.7 cents ($1.12 annualized) per share, yielding 2.7% at the current stock price; NI's payout ratio is 60%, with a five-year dividend growth rate of 6.22%

    80% confidence
  • Real GDP growth is expected to hover near 2% for 2026, reflecting a slowdown from post-pandemic peaks but signaling continued economic resilience rather than contraction

    80% confidence
  • Johnson & Johnson's biggest strength is its diversified business model operating through pharmaceuticals and medical devices divisions with more than 275 subsidiaries

    80% confidence
  • NiSource is benefiting from consistent investments to strengthen its infrastructure and expects to invest $28 billion in 2026-2030 in modernizing infrastructure

    80% confidence
  • NiSource carries a Zacks Rank #2 (Buy)

    80% confidence
  • Strategic alliances and Morgan Stanley's increased focus on less capital market-dependent operations are expected to aid growth, with enhanced capital distribution activities reflecting a solid balance sheet

    80% confidence
  • Real GDP rebounded sharply in the second quarter of 2025, expanding 3.8%, according to the U.S. Bureau of Economic Analysis's third estimate, marking a 0.5-percentage-point upward revision driven primarily by stronger-than-expected consumer spending

    80% confidence
  • Invesco's robust AUM balance, diverse product offerings, strong balance sheet and global presence will keep supporting financials; synergies from acquisitions will keep aiding profitability

    80% confidence
  • Since 2000, Zacks top stock-picking strategies have achieved average gains of +48.4%, +50.2% and +56.7% per year, versus the S&P's +7.7% average gain per year

    80% confidence
  • Johnson & Johnson pays out a quarterly dividend of $1.30 ($5.20 annualized) per share, with a 2.52% yield at the current stock price; JNJ's payout ratio is 50%, with a five-year dividend growth rate of 5.39%

    80% confidence
  • Inflation is projected to gradually moderate in 2026, allowing the Federal Reserve greater flexibility to pivot toward a more accommodative policy stance

    80% confidence
  • NiSource expects to invest $28 billion in 2026-2030 in modernizing infrastructure to enhance the reliability of its operations

    80% confidence
  • NiSource carries a Zacks Rank #2 (Buy)

    80% confidence
  • The labor market cooled in 2025, with unemployment rising to 4.6%, its highest level in several years

    80% confidence
  • The labor market cooled in 2025, with unemployment rising to 4.6%, its highest level in several years, and wage growth trending lower

    80% confidence
  • Inflation remained above the Federal Reserve's 2% target in 2025, even as price pressures eased slightly later in the year

    80% confidence
  • Morgan Stanley pays out a quarterly dividend of $1.00 ($4.00 annualized) per share, with a 2.26% yield at the current stock price; MS's payout ratio is 41%, with a five-year dividend growth rate of 20.35%

    80% confidence
  • Johnson & Johnson has more than 275 subsidiaries, reflecting an extremely well diversified business

    80% confidence

Data points we hold from this source

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Chip Boom Lifts Semiconductors as Export-Control Gaps Persist
AI infrastructure demand is fueling a broad semiconductor rally — Broadcom's AI chip revenue and Q4 guidance, Amazon's custom silicon crossing a $25B annual run rate, and bullish analyst calls on Micron and Sandisk tied to a memory chip boom underestimated even by bulls — with ASML rallying on sympathy. That momentum runs alongside unresolved US-China tech tensions: Belgium's arrest of a suspect for stealing chip technology for China and a blacklisted Chinese firm still acquiring Nvidia's top AI chips show export-control enforcement lagging the pace of AI chip demand.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts record the same attribute (net_income) for JPMorgan Chase & Co. in the identical fiscal period (Q1 2026) and observation date (2026-03-31), but report values that differ by approximately 1 billion times: $16,494,000,000 vs $16.49. These cannot both be true simultaneously. The discrepancy suggests either a unit mismatch (e.g., one is total net income, the other earnings per share mislabeled as net_income), a decimal point error, or data entry corruption. For the same entity, attribute, and time period, only one value can be correct.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,280 source documents archived
Query this data → isubstrate.com
The Zacks Analyst Blog Highlights Invesco, Johnson & Johnson, NiSource, Bunge Global and Morgan Stanley — Source | Via News | Finance Via News